ReviewThe British journal of radiology2022
Proton therapy for prostate cancer: current state and future perspectives.
Review in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Diagnostic performance based on MRI for preoperative of vessels encapsulating tumor clusters in hepatocellular carcinoma: a systematic review and meta-analysis.La Radiologia medica · 2025Pooled it
- Omission of lateral isocenter shifts in robust optimization of proton therapy treatment plans for prostate cancer.Journal of applied clinical medical physics · 2026Article
- Predictors of acute genitourinary toxicity in real-time image-gated spot-scanning proton beam therapy for prostate cancer.Journal of radiation research · 2026Article
- Feasibility and Outcomes of Perirectal Spacer Implantation in Previously Treated Prostate Cancer Patients Undergoing Salvage Proton Therapy Radiation.Advances in radiation oncology · 2026Article
- Dosimetric benefits of half-field arc in prostate cancer treatment.Physical and engineering sciences in medicine · 2026Article
- A Comprehensive Review of Nanotechnological Innovations in Cancer: from Molecular Pathways to Clinical Applications.Journal of Cancer · 2026Review
- Integration of X-Ray and γ-Ray technologies in lattice radiotherapy: a novel approach for optimizing dose delivery in large-volume non-small cell lung cancer.Radiation oncology (London, England) · 2025Article
- Dosimetric effect of internal error correction on pubic bones in image-guided passive scattering proton therapy for prostate cancer.Journal of radiation research · 2025Article
- Article
- Hypofractionated Radiotherapy for Prostate Cancer: A Comparative Study of Clinical Outcomes and Dosimetry Between Proton and Photon Therapy.Cancer management and research · 2025Article
- Wharton's jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury.World journal of stem cells · 2024Review
- Evaluation of magnetic resonance imaging derived synthetic computed tomography for proton therapy planning in prostate cancer.Physics and imaging in radiation oncology · 2024Article
- Article
- Pencil Beam Scanning Proton Bragg Peak Conformal FLASH in Prostate Cancer Stereotactic Body Radiotherapy.Cancers · 2024Article
- Article
- Innovations in prostate cancer: introductory editorial.The British journal of radiology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLocalized prostate cancer can be treated with several radiotherapeutic approaches. Proton therapy (PT) can precisely target tumors, thus sparing normal tissues and reducing side-effects without sacrificing cancer control. However, PT is a costly treatment compared with conventional photon radiotherapy, which may undermine its overall efficacy. In this review, we summarize current data on the dosimetric rationale, clinical benefits, and cost of PT for prostate cancer.
methodsAn extensive literature review of PT for prostate cancer was performed with emphasis on studies investigating dosimetric advantage, clinical outcomes, cost-effective strategies, and novel technology trends.
resultsPT is safe, and its efficacy is comparable to that of standard photon-based therapy or brachytherapy. Data on gastrointestinal, genitourinary, and sexual function toxicity profiles are conflicting; however, PT is associated with a low risk of second cancer and has no effects on testosterone levels. Regarding cost-effectiveness, PT is suboptimal, although evolving trends in radiation delivery and construction of PT centers may help reduce the cost.
conclusionPT has several advantages over conventional photon radiotherapy, and novel approaches may increase its efficacy and safety. Large prospective randomized trials comparing photon therapy with proton-based treatments are ongoing and may provide data on the differences in efficacy, toxicity profile, and quality of life between proton- and photon-based treatments for prostate cancer in the modern era. ADVANCES IN KNOWLEDGE: PT provides excellent physical advantages and has a superior dose profile compared with X-ray radiotherapy. Further evidence from clinical trials and research studies will clarify the role of PT in the treatment of prostate cancer, and facilitate the implementation of PT in a more accessible, affordable, efficient, and safe way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.